Advances in the detection and quantification of candidate and established biomarkers in heart failure

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;30:1787-1847.Search in Google Scholar

2. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949-52.10.1161/CIRCULATIONAHA.106.68311017325253Search in Google Scholar

3. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:99-109.Search in Google Scholar

4. Van Kimmenade RRJ, Januzzi JL. Emerging biomarkers in heart failure. Clin Chem 2012;58(1):127-138.10.1373/clinchem.2011.16572022086968Search in Google Scholar

5. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Bat Biotechnol 2006;24(8):971-83.10.1038/nbt123516900146Search in Google Scholar

6. Mongra AC, Kaur A. Biosensors activities around the globe. Dig J Nanomat Biostruct 2012;7(4):1457-71.Search in Google Scholar

7. Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013, http://dx.-doi.org/10.1016/j.bbadis.2012.12.01410.1016/j.bbadis.2012.12.01423313577Search in Google Scholar

8. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-5910.1056/NEJMra080023918480207Search in Google Scholar

9. McCullough PA, Nowal RM, McCord J, Hollander JE, Herrmann HC, Steg PG et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106(4):416-22.10.1161/01.CIR.0000025242.79963.4C12135939Search in Google Scholar

10. De Keijzer MH, Perkins S, Motta V, Morelli D, Cristol JP, Dupuy AM et al. Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer. Clin Lab 2009;55(9-10):363-70.Search in Google Scholar

11. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42(1):37-44.10.1515/CCLM.2004.00815061378Search in Google Scholar

12. Yi W, Liang W, Li P, Li S, Zhang Z, Yang M et al. Application of a Fab fragment of monoclonal antibody specific to N-terminal pro-brain natriuretic peptide for the detection based on regeneration-free electrochemical immunosensor. Biotechnol Lett. 2011;33(8):1539-4310.1007/s10529-011-0600-121452014Search in Google Scholar

13. Liang W, Li Y, Zhang B, Zhang Z, Chen A, Qi D, Yi W, Hu C. A novel microfluidic immunoassay system based on electrochemical immunosensors: an application for the detection of NT-proBNP in whole blood. Biosens Bioelectron. 2012;31(1):480-510.1016/j.bios.2011.11.02122169814Search in Google Scholar

14. Zhuo Y, Yi WJ, Lian WB, Yuan R, Chai YQ, Chen A, Hu CM. Ultrasensitive electrochemical strategy for NTproBNP detection with gold nanochains and horseradish peroxidase complex amplification. Biosens Bioelectron. 2011;26(5):2188-9310.1016/j.bios.2010.09.03320952179Search in Google Scholar

15. Fonarow GC, Peacock WF, Phillips CO et al. Admission B-type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated HF. J Am Coll Cardiol 2007;49:1943-50.10.1016/j.jacc.2007.02.03717498579Search in Google Scholar

16. Di Somma S, Magrini L, Pittoni V et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute HF: the Italian RED Study. Crit Care 2010;14:R116.10.1186/cc9067291176320550660Search in Google Scholar

17. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-954.10.1016/j.amjcard.2004.12.03215820160Search in Google Scholar

18. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes- Genis A, Ordonez-Llanos J, Santalo-Bel M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NTproBNP Study. Eur Heart J 2006;3:341-9Search in Google Scholar

19. Moe GW, Howlett J, Januzzi JL et al. N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute HF: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study. Circulation 2007;115:3103-10.10.1161/CIRCULATIONAHA.106.66625517548729Search in Google Scholar

20. Maiser A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikwski P et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.10.1016/j.jacc.2010.02.02520447528Search in Google Scholar

21. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51(10):1823-910.1373/clinchem.2005.05111016099941Search in Google Scholar

22. Missbichler A, Hawa G, Schmal N, Woloszczuk W.Search in Google Scholar

Sandwich ELISA for proANP 1-98 facilitates investigation of left ventricular dysfunction. Eur J Med Res 2001;6(3):105-11.Search in Google Scholar

23. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6.10.1161/01.CIR.0000047274.66749.FESearch in Google Scholar

24. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49.10.1172/JCI30634186502717492053Search in Google Scholar

25. Rehman SU, Mueller T, Januzzi JL. Characteristics of novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-65.10.1016/j.jacc.2008.07.04219017513Search in Google Scholar

26. Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. Clin Chim Acta 2009;409(1-2):33-40.10.1016/j.cca.2009.08.01019699192Search in Google Scholar

27. Mueller T, Dieplinger B. The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay formeasurement of soluble ST2. Expert Rev Mol Diagn 2013;13(1):13-30.10.1586/erm.12.128Search in Google Scholar

28. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin 2009;5:537-47.10.1016/j.hfc.2009.04.006Search in Google Scholar

29. Darmanis S, Nong RY, Hammond M, Gu J, Alderborn A, Vänelid J et al. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics 2010;9(2):327-3510.1074/mcp.M900248-MCP200Search in Google Scholar

30. Kempf T, von Haehling S, Peter T, Allhof T, Cicoira M, Doehner W et al. Prognostic utility of growth differentiation factor-15 in patients with chronic HF. J Amer Card 2007;50:1054-60.10.1016/j.jacc.2007.04.091Search in Google Scholar

31. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C et al. The novel biomarker growth differentiation factor 15 in HF with normal ejection fraction. Eur J Heart Fail 2010;12:1309-16.10.1093/eurjhf/hfq151Search in Google Scholar

32. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;2:243-9.10.1016/S1071-9164(96)80047-9Search in Google Scholar

33. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-91.10.1161/01.CIR.0000057810.48709.F612654604Search in Google Scholar

34. Abe K, Hashimoto Y, Yatsushiro S, Yamamura S, Bando M, Hiroshima Y et al. Simultaneous immunoassay analysis of plasma IL-6 and TNF-α on a microchip. PLoS One 2013;8(1):e5362010.1371/journal.pone.0053620354114123326472Search in Google Scholar

35. Tekin HC, Cornaglia M, Gijs MA. Attomolar protein detection using a magnetic bead surface coverage assay. Lab Chip 2013;13(6):1053-9.10.1039/c3lc41285g23392210Search in Google Scholar

36. Brudaşcă I, Cucuianu M. Chronic Stress, Neuroendocrine Disorders and Metabolic Syndrome. Rev Romana Med Lab 2011;19(3):219-226Search in Google Scholar

37. Kalogeropoulos A, Georgiopoulos V, Psaty BM, Rodondi N, Smith AL, Harrison DG et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging and Body Composition) study. J Am Coll Cardiol 2010;55:2129-37.10.1016/j.jacc.2009.12.045326779920447537Search in Google Scholar

38. Miramontes Espino MV, Romero-Prado MM. Patented Aptamers For C-Reactive Protein Detection: A Review About Their Use In Clinical Diagnostics. Recent Pat DNA Gene Seq. 2013. (Epub ahead of print)10.2174/18722156070314020412254323521704Search in Google Scholar

39. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81.10.1016/j.ahj.2007.08.01318082493Search in Google Scholar

40. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27(1):161-7.10.1161/01.ATV.0000252126.48375.d517095712Search in Google Scholar

41. Vida-Simiti L, Cristea A. Serum levels of TRAIL OPG and RANKL in patients with severe heart failure. Rev Romana Med Lab 2010;18(4):17-23Search in Google Scholar

42. Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, Hazen SL. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006;98:796-9.10.1016/j.amjcard.2006.04.01816950188Search in Google Scholar

43. Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Areja N et al. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 2010;56:944-51.10.1373/clinchem.2009.14225720413430Search in Google Scholar

44. Saravanan L, Juneja S. Immunohistochemistry is a more sensitive marker for the detection of myeloperoxidase in acute myeloid leukemia compared with flow cytometry and cytochemistry. Int J Lab Hematol 2010;32(1):e132-610.1111/j.1751-553X.2008.01124.x19077157Search in Google Scholar

45. Buralli S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E et al. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 2010;105:853-6.10.1016/j.amjcard.2009.11.03820211331Search in Google Scholar

46. Hawkes SP, Li H, Taniguchi GT. Zymography and reverse zymography for detecting MMPs and TIMPs. Methods Mol Biol 2010;622:257-69.10.1007/978-1-60327-299-5_1620135288Search in Google Scholar

47. Frantz S, Stork S, Michels K, Eigenthaler M, Ertl G, Bauersachs J et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008;10:388-95.10.1016/j.ejheart.2008.02.01518343723Search in Google Scholar

48. Lok DJ, Van Der Meer P, de la Porte PW. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic HF: data from the DEAL-HF study. Clin Res Cardiol 2010;99-323-28.10.1007/s00392-010-0125-y285879920130888Search in Google Scholar

49. Kolla V, Jenö P, Moes S, Lapaire O, Hoesli I, Hahn S. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol 2012;2012:30596410.1155/2012/305964Search in Google Scholar

50. Park YK, Bold B, Lee WK, Jeon MH, An KH, Jeong SY, Shim YK. d-(+)-Galactose-Conjugated Single-Walled Carbon Nanotubes as New Chemical Probes for Electrochemical Biosensors for the Cancer Marker Galectin-3. Int J Mol Sci 2011;12(5):2946-57.10.3390/ijms12052946Search in Google Scholar

51. Săvoiu G, Cristescu C, Şerban C, Noveanu L, Borza C, Dehelean C, et al. Endothelin-1 plasma concentration in patients with essential hypertension, atherogenic dyslipidemia and coronary artery disease. Rev Romana Med Lab 2010;18(4):25-30Search in Google Scholar

52. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol 2012;21(5):365-71.10.1016/j.carpath.2011.11.007Search in Google Scholar

53. Francis GS. Neurohormonal control of heart failure. Cleve Clin J Med 2011;78:S75-9. 10.3949/ccjm.78.s1.13Search in Google Scholar

54. Laricchia-Robbio L, Moscato S, Guidi A, Viganò S, Rovero P, Revoltella RP. Detection and epitope mapping of immunoreactive human endothelin-1 using ELISA and a surface plasmon resonance-based biosensor. Biosens Bioelectron 1997;12(8):765-78.10.1016/S0956-5663(97)00043-2Search in Google Scholar

55. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P et al. Evaluation of multiple markers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012;125:233-40.10.1161/CIRCULATIONAHA.111.063842327728722179538Search in Google Scholar

56. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006;52(6):1144-51.10.1373/clinchem.2005.06558116627560Search in Google Scholar

57. Thomas A, Solymos E, Schänzer W, Baume N, Saugy M, Dellanna F, Thevis M. Determination of Vasopressin and Desmopressin in urine by means of liquid chromatography coupled to quadrupole time-of-flight mass spectrometry for doping control purposes. Anal Chim Acta 2011;707(1-2):107-13.10.1016/j.aca.2011.09.02722027126Search in Google Scholar

58. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of disease. J Am Coll Cardiol 2008;52:266-72.10.1016/j.jacc.2008.03.05018634981Search in Google Scholar

59. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52(1):112-9.10.1373/clinchem.2005.06003816269513Search in Google Scholar

60. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.10.1161/CIRCULATIONAHA.106.65507617698733Search in Google Scholar

61. Apple FS, Collinson PO. Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays. Clin Chem 2012;58:54-6110.1373/clinchem.2011.16579521965555Search in Google Scholar

62. Moreira FT, Dutra RA, Noronha JP, Cunha AL, Sales MG. Artificial antibodies for troponin T by its imprinting on the surface of multiwalled carbon nanotubes: its use as sensory surfaces. Biosens Bioelectron 2011;28(1):243-50.10.1016/j.bios.2011.07.02621816602Search in Google Scholar

63. Abad L, Javier del Campo F, Muñoz FX, Fernández LJ, Calavia D, Colom G et al. Design and fabrication of a COP-based microfluidic chip: chronoamperometric detection of Troponin T. Electrophoresis 2012;33(21):3187-94.10.1002/elps.20120022523065680Search in Google Scholar

64. Shen W, Tian D, Cui H, Yang D, Bian Z. Nanoparticle- based electrochemiluminescence immunosensor with enhanced sensitivity for cardiac troponin I using N- (aminobutyl)-N-(ethylisoluminol)-functionalized gold nanoparticles as labels. Biosens Bioelectron 2011;27(1):18-24.10.1016/j.bios.2011.05.02221752633Search in Google Scholar

65. Allen LA, Felker MG. Multi-marker strategies in heart failure: clinical and statistical approaches. Heart Fail Rev 2010;15:343-9.10.1007/s10741-009-9144-z396158219412735Search in Google Scholar

66. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A et al . Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.10.1056/NEJMoa070706418480203Search in Google Scholar

67. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006;152:94-101.10.1016/j.ahj.2005.09.02016824837Search in Google Scholar

68. Ralli S, Horwich TB, Fonarow GC. Relationship between anemia, cardiac troponin I and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005;150:1220-1227.10.1016/j.ahj.2005.01.04916338262Search in Google Scholar

69. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392:41-45.10.1016/j.cca.2008.03.00218387360Search in Google Scholar

70. Van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24.10.1016/j.jacc.2006.03.06116979009Search in Google Scholar

71. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Pro-A-type natriuretic peptide, proadrenomedullin, and Nterminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. J Card Fail 2013;19(1):31-9.10.1016/j.cardfail.2012.11.00223273592Search in Google Scholar

72. Eurlings LW, Sanders-van Wijk S, van Kimmenade R, Osinski A, van Helmond L, Vallinga M et al. Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score. J Am Coll Cardiol 2012;60(17):1668-77.10.1016/j.jacc.2012.06.04023021334Search in Google Scholar

73. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126(13):1596-604.10.1161/CIRCULATIONAHA.112.129437365671922907935Search in Google Scholar

74. Lu W, Fu C, Chen Y, Lu J, Yao Y, Shen C, Gu Z. Multiplex detection of B-type natriuretic peptide, cardiac troponin I and C-reactive protein with photonic suspension array. PLoS One 2012;7(7):e4144810.1371/journal.pone.0041448340722722848497Search in Google Scholar

75. Park J, Sunkara V, Kim TH, Hwang H, Cho YK. Lab-on-a-disc for fully integrated multiplex immunoassays. Anal Chem 2012; 84(5):2133-40. 10.1021/ac203163u22277086Search in Google Scholar